APOA1 and atherosclerosis: Likewise, in rabbit models of atherosclerosis, infusions of a commercial apoA-IM/phospholipid complex, ETC-216, have been shown to induce rapid plaque regression based on assessment by intravascular ultrasound (IVUS) or magnetic resonance imaging [55,56].